Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.33 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25235166 | 0.76 | ALDH1A1 (0.46) | ALDH1A1PANK3MEN1KMT2AATM | |
| SCHEMBL594933 | 0.72 | L3MBTL1 (0.36) | MEN1KMT2ALMNARAB9A | |
| SCHEMBL3628852 | 0.70 | MEN1 (0.37) | MEN1KMT2AATMLMNA | |
| SCHEMBL593900 | 0.68 | PDE2A (0.33) | — | |
| SCHEMBL2925593 | 0.66 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL1514828 | 0.65 | MC4R (0.47) | ALDH1A1HRH3MEN1KMT2A | |
| SCHEMBL1514935 | 0.65 | OGA (0.41) | ALDH1A1HRH3KMT2AOGALMNA | |
| SCHEMBL3106200 | 0.65 | ALDH1A1 (0.43) | ALDH1A1OGA | |
| SCHEMBL27571753 | 0.64 | CYP2D6 (0.71) | ALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL208307 | 0.64 | ALDH1A1 (0.51) | ALDH1A1HRH3KMT2AOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114872-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | ALDH1A1 578/4885HRH3 3703/4885PANK3 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.